These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 38558973)

  • 1. Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.
    Chao CW; Sprouse KR; Miranda MC; Catanzaro NJ; Hubbard ML; Addetia A; Stewart C; Brown JT; Dosey A; Valdez A; Ravichandran R; Hendricks GG; Ahlrichs M; Dobbins C; Hand A; Treichel C; Willoughby I; Walls AC; McGuire AT; Leaf EM; Baric RS; Schäfer A; Veesler D; King NP
    bioRxiv; 2024 Mar; ():. PubMed ID: 38558973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive protection across divergent subgroups.
    Hutchinson G; Abiona O; Ziwawo C; Werner A; Ellis D; Tsybovsky Y; Leist S; Palandjian C; West A; Fritch E; Wang N; Wrapp D; Boyoglu-Barnum S; Ueda G; Baker D; Kanekiyo M; McLellan J; Baric R; King N; Graham B; Corbett K
    Res Sq; 2022 Nov; ():. PubMed ID: 36380759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera.
    Hutchinson GB; Abiona OM; Ziwawo CT; Werner AP; Ellis D; Tsybovsky Y; Leist SR; Palandjian C; West A; Fritch EJ; Wang N; Wrapp D; Boyoglu-Barnum S; Ueda G; Baker D; Kanekiyo M; McLellan JS; Baric RS; King NP; Graham BS; Corbett-Helaire KS
    Nat Commun; 2023 Oct; 14(1):6195. PubMed ID: 37794071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection.
    Tai W; Zheng J; Zhang X; Shi J; Wang G; Guan X; Zhu J; Perlman S; Du L
    Virus Res; 2023 Sep; 334():199156. PubMed ID: 37336390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
    Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2.
    Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP
    bioRxiv; 2020 Aug; ():. PubMed ID: 32817941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice.
    Martinez DR; Schafer A; Gavitt TD; Mallory ML; Lee E; Catanzaro NJ; Chen H; Gully K; Scobey T; Korategere P; Brown A; Smith L; Parks R; Barr M; Newman A; Bowman C; Powers JM; Mansouri K; Edwards RJ; Baric RS; Haynes BF; Saunders KO
    bioRxiv; 2023 May; ():. PubMed ID: 37293083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans.
    Addetia A; Stewart C; Seo AJ; Sprouse KR; Asiri AY; Al-Mozaini M; Memish ZA; Alshukairi A; Veesler D
    bioRxiv; 2024 Apr; ():. PubMed ID: 38617298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.
    Ma C; Wang L; Tao X; Zhang N; Yang Y; Tseng CK; Li F; Zhou Y; Jiang S; Du L
    Vaccine; 2014 Oct; 32(46):6170-6176. PubMed ID: 25240756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
    Kim MH; Kim HJ; Chang J
    PLoS One; 2019; 14(7):e0220196. PubMed ID: 31329652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice.
    Martinez DR; Schäfer A; Gavitt TD; Mallory ML; Lee E; Catanzaro NJ; Chen H; Gully K; Scobey T; Korategere P; Brown A; Smith L; Parks R; Barr M; Newman A; Bowman C; Powers JM; Soderblom EJ; Mansouri K; Edwards RJ; Baric RS; Haynes BF; Saunders KO
    Cell Rep; 2023 Oct; 42(10):113248. PubMed ID: 37858337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans.
    Addetia A; Stewart C; Seo AJ; Sprouse KR; Asiri AY; Al-Mozaini M; Memish ZA; Alshukairi AN; Veesler D
    Cell Rep; 2024 Aug; 43(8):114530. PubMed ID: 39058596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP
    Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
    Dai L; Zheng T; Xu K; Han Y; Xu L; Huang E; An Y; Cheng Y; Li S; Liu M; Yang M; Li Y; Cheng H; Yuan Y; Zhang W; Ke C; Wong G; Qi J; Qin C; Yan J; Gao GF
    Cell; 2020 Aug; 182(3):722-733.e11. PubMed ID: 32645327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
    Tai W; Zhao G; Sun S; Guo Y; Wang Y; Tao X; Tseng CK; Li F; Jiang S; Du L; Zhou Y
    Virology; 2016 Dec; 499():375-382. PubMed ID: 27750111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD.
    Wang N; Rosen O; Wang L; Turner HL; Stevens LJ; Corbett KS; Bowman CA; Pallesen J; Shi W; Zhang Y; Leung K; Kirchdoerfer RN; Becker MM; Denison MR; Chappell JD; Ward AB; Graham BS; McLellan JS
    Cell Rep; 2019 Sep; 28(13):3395-3405.e6. PubMed ID: 31553909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bioengineered pseudovirus nanoparticle displaying SARS-CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS-CoV 2 challenge.
    Xia M; López K; Vago FS; Huang P; Auguste DI; Jiang W; Auguste AJ; Tan M
    Biotechnol J; 2023 Oct; 18(10):e2300130. PubMed ID: 37300425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.